Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

tag donanemab

Biogen, Eisai Alzheimer’s drug lecanemab fast tracked by FDA

pharmaphorum

DECEMBER 24, 2021

The anti-amyloid drug, which also claimed a breakthrough tag from the FDA in July, is being developed for the treatment of early-stage Alzheimer’s disease. The $56,000-a-year price tag for the drug, which has now been cut in half in the US, also hasn’t helped the drugmakers make a case for Aduhelm with US payers.

Drugs

Drugs FDA Approval Trials Marketing

Roche’s Early Alzheimer’s Blood Test Gets FDA Breakthrough Device Designation

XTalks

APRIL 18, 2024

Alongside its partnership with Roche on diagnostics, Lilly is also developing an amyloid beta therapy of its own, donanemab. Previously, Roche secured an FDA breakthrough tag for another one of its Alzheimer’s blood tests that detects levels of pTau-181 and ApoE4 (apolipoprotein e4).

Clinical Trials

Clinical Trials Clinical Trials In-Vitro Protein

Biogen, Eisai Alzheimer’s drug lecanemab fast tracked by FDA

Roche’s Early Alzheimer’s Blood Test Gets FDA Breakthrough Device Designation

Stay Connected